Cargando…

A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer

The epithelial-to-mesenchymal transition (EMT) is an essential developmental process which can be hijacked by cancer cells, leading to enhanced metastasis and chemoresistance in experimental models. Recent studies have linked gene expression of EMT-associated gene signatures to increased inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales: Block, C. James, Dyson, Gregory, Campeanu, Ion John, Watza, Donovan, Ratnam, Manohar, Wu, Guojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882801/
https://www.ncbi.nlm.nih.gov/pubmed/31780722
http://dx.doi.org/10.1038/s41598-019-54282-z
_version_ 1783474240433946624
author Block, C. James
Dyson, Gregory
Campeanu, Ion John
Watza, Donovan
Ratnam, Manohar
Wu, Guojun
author_facet Block, C. James
Dyson, Gregory
Campeanu, Ion John
Watza, Donovan
Ratnam, Manohar
Wu, Guojun
author_sort Block, C. James
collection PubMed
description The epithelial-to-mesenchymal transition (EMT) is an essential developmental process which can be hijacked by cancer cells, leading to enhanced metastasis and chemoresistance in experimental models. Recent studies have linked gene expression of EMT-associated gene signatures to increased inflammatory immune response in multiple cancer types. However, these studies did not account for the potential confounding effects of gene expression by tumor-infiltrating mesenchymal stromal cells. In this study, we comprehensively dissect the associations between multiple EMT transcription factors and EMT markers with stromal and immune tumor infiltration. We find that EMT-related genes are highly correlated with intratumoral stromal cell abundance and identify a specific relationship between stroma-corrected ZEB1 expression and decreased immune activity in multiple cancer types. We derive a stroma-corrected ZEB1-activated transcriptional signature and demonstrate that this signature includes several known inhibitors of inflammation, including BMPR2. Finally, multivariate survival analysis reveals that ZEB1 and its expression signature are significantly associated with reduced overall survival in breast cancer patients. In conclusion, this study identifies a novel association between stroma-adjusted ZEB1 expression and tumor immune activity and addresses the critical issue of confounding between EMT-associated genes and tumor stromal content.
format Online
Article
Text
id pubmed-6882801
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-68828012019-12-06 A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer Block, C. James Dyson, Gregory Campeanu, Ion John Watza, Donovan Ratnam, Manohar Wu, Guojun Sci Rep Article The epithelial-to-mesenchymal transition (EMT) is an essential developmental process which can be hijacked by cancer cells, leading to enhanced metastasis and chemoresistance in experimental models. Recent studies have linked gene expression of EMT-associated gene signatures to increased inflammatory immune response in multiple cancer types. However, these studies did not account for the potential confounding effects of gene expression by tumor-infiltrating mesenchymal stromal cells. In this study, we comprehensively dissect the associations between multiple EMT transcription factors and EMT markers with stromal and immune tumor infiltration. We find that EMT-related genes are highly correlated with intratumoral stromal cell abundance and identify a specific relationship between stroma-corrected ZEB1 expression and decreased immune activity in multiple cancer types. We derive a stroma-corrected ZEB1-activated transcriptional signature and demonstrate that this signature includes several known inhibitors of inflammation, including BMPR2. Finally, multivariate survival analysis reveals that ZEB1 and its expression signature are significantly associated with reduced overall survival in breast cancer patients. In conclusion, this study identifies a novel association between stroma-adjusted ZEB1 expression and tumor immune activity and addresses the critical issue of confounding between EMT-associated genes and tumor stromal content. Nature Publishing Group UK 2019-11-28 /pmc/articles/PMC6882801/ /pubmed/31780722 http://dx.doi.org/10.1038/s41598-019-54282-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Block, C. James
Dyson, Gregory
Campeanu, Ion John
Watza, Donovan
Ratnam, Manohar
Wu, Guojun
A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer
title A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer
title_full A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer
title_fullStr A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer
title_full_unstemmed A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer
title_short A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer
title_sort stroma-corrected zeb1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882801/
https://www.ncbi.nlm.nih.gov/pubmed/31780722
http://dx.doi.org/10.1038/s41598-019-54282-z
work_keys_str_mv AT blockcjames astromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT dysongregory astromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT campeanuionjohn astromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT watzadonovan astromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT ratnammanohar astromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT wuguojun astromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT blockcjames stromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT dysongregory stromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT campeanuionjohn stromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT watzadonovan stromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT ratnammanohar stromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer
AT wuguojun stromacorrectedzeb1transcriptionalsignatureisinverselyassociatedwithantitumorimmuneactivityinbreastcancer